Licensing Executive Society Awards the "Deal of Distinction" Prize for Top Licensing Agreement in the Industry-University-Government Category
NEW YORK CITY (September 13, 2006) -- The Global Alliance for TB Drug Development (TB Alliance) and Bayer HealthCare AG today were awarded top honors from the Licensing Executive Society (USA and Canada) for an innovative agreement allowing the start of global clinical trials of a drug that may prove effective in treating tuberculosis (TB).
The prestigious 2005 Deal of Distinction Award recognizes worthy transactions involving the transfer and licensing of intellectual property using creative and innovative solutions to business issues. This year, the award was given to only six deals.
"The partnership between the TB Alliance and Bayer Healthcare required a fresh look at how to leverage the strengths of private and public organizations to solve a global health crisis of growing proportion," said Gerald J. Siuta, PhD, of the TB Alliance. "We are proud of this agreement and honored to receive the recognition from LES."